Anti-LIF Monoclonal antibody, clone 8E3

Various factors affecting the random and systematic error in the repeatability and reproducibility of thermoluminescent (LiF)-Li-6:Mg,Ti dosimeters were investigated. These characteristics were examined by irradiating them at different doses in the range 3.8 mu G to 433.94 mGy from a Cs-137 gamma source. Values of the element correction factors (ECFs) were obtained by exposing the chips to a dose of 433.93 mGy five times. This investigation denotes that more correction will be obtained by calculating the error due to non-subtracting zero dose reading from the delivered dose, which decreases the coefficient of variation as a percentage of the mean from the range of 2.4%-18.6% to only 0.7%-16.9% Using the individual sensitivity factor and repeating five calibrations decreases the coefficient of variation as a percentage of the mean to only 0.54%. The values of the Variability Index for System (SVI), Reader (RVI) and Detector (DVI) are 1.46 %, 1.40% and 0.34% respectively. Also, it is clear from the results that the best repeatability and reproducibility obtained by using the element correction factor was associated with each dosimeter rather than carefully selecting the individual dosimeters. Finally, from the results, it can be noted that at low doses, the value of relative coefficient of variation becomes very large, while at high doses, it becomes basically constant and of the order of a few percentage.

Background Stimulation of ovulation with clomiphene citrate can cause side effects on endometrial receptivity. Formulation with nano-size may be an alternative therapy for women with ovulatory disorders. In this study, we investigated sustained-release clomiphene citrate by using Phosal-based formulation (PBF) and evaluate its decreased side effect on the endometrial receptivity. Methods In the in-vitro study, CC loaded PBF was analyzed using Zetasizer, Fourier-transform infrared spectroscopy (FTIR), and Transmission electron microscopy (TEM). In the in-vivo study, 24 female mice were randomly divided into three groups: CC (5 mg/kg), CC/PBF (5 mg/kg) and SS (1 ml) daily administered and injected with 5 IU HCG and mated after two days. At day 4.5, pregnant mice were euthanized and endometrial tissue was extracted for quantitative polymerase chain reaction (Q-PCR) analysis. Results The optimized PBF contained Phosal 50PG/glycerol in a 2:8 ratios (w/w) and the particle size of optimum formulation was 67 +/- 0.30551 nm and the release of CC from CC-containing PBF was slightly faster in the first 24 h; wherein, 29% of CC was released, and 76% of CC was released up to 120 h. The mRNA levels of leukemia inhibitory factor (LIF), leukemia inhibitory factor receptor alpha (LIFR), HOXA10, Heparin-binding epidermal growth factor (HB-EGF), and epidermal growth factor (EGF) were significantly upregulated and MUC1 and PGR mRNA levels were significantly downregulated in the CC-containing PBF-treated animals compared with only CC group (P < 0.05). Conclusion Sustained release formulation of clomiphene citrate increased its targeting efficiency and improved the impact of the CC on implantation. Graphical abstract A new Phosal Based Formulation (PBF) was designed to decrease the side effects of Clomiphene citrate (CC) on endometrium. This drug formulation could react better during implantation by increasing the expression of genes involved in implantation. The in vivo study demonstrated that the CC-containing PBF in mice has a significantly higher endometrial receptivity, compared with the suspension.